5-Amino-1MQ vs P21 (Cerebrolysin Analog)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

5-Amino-1MQP21 (Cerebrolysin Analog)
CategoryPeptidesPeptides
Standard DoseResearch indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
TimingMorning dosing preferred. Can be taken with or without food.Morning dosing preferred for cognitive effects.
Cycle Duration8-12 week cycles.4-8 week cycles with 4-week rest periods.
Evidence Levelanimal_plus_anecdotalanimal_plus_anecdotal
A

5-Amino-1MQ

Peptides

Mechanism

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.

Standard Dosing

Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.

Timing

Morning dosing preferred. Can be taken with or without food.

Cycle Duration

8-12 week cycles.

Side Effects

  • Mild GI discomfort
  • Headache
  • Diarrhea (uncommon)
  • Nausea at higher doses

Contraindications

  • Pregnancy and breastfeeding
  • Severe hepatic impairment
  • Active cancer (NAD+ modulation concern)

Best Stacking Partners

MOTS-cAOD-9604TesofensineSemaglutide

Mechanism

P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.

Standard Dosing

Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.

Timing

Morning dosing preferred for cognitive effects.

Cycle Duration

4-8 week cycles with 4-week rest periods.

Side Effects

  • Mild headache
  • Nasal irritation (intranasal)
  • Increased appetite (CNTF pathway modulation)
  • Vivid dreams

Contraindications

  • Pregnancy and breastfeeding
  • Active seizure disorders

Best Stacking Partners

SemaxSelankDihexa

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →